The Dudley Group NHS Foundation Trust has accelerated the roll-out of a pioneering information sharing project to support its clinicians during the coronavirus outbreak.
The trust is one of the first in the UK to adopt the Allscripts dbMotion information sharing platform, and was planning a full-scale deployment this summer, following internal testing and a proof of concept with local GPs.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of its remote monitoring and defibrillator solution (Tempus ALS) for pre-hospital settings in the U.S. The solution is a complete end-to-end system that combines innovative hardware and advanced software to expand the pre-hospital scope of care for first responders. 
An early warning system that helps busy doctors, nurses and other healthcare professionals to quickly identify when patients are at risk of deterioration is to be deployed across hospitals and community settings throughout Lanarkshire. 
IBM (NYSE: IBM) Watson Health® announced its 2020 Fortune/IBM Watson Health 100 Top Hospitals list and 15 Top Health Systems award winners, naming the top-performing hospitals and health systems in the U.S. Extrapolating the results of this year's studies, if all Medicare hospitalized patients received the same level of care as those treated in the award-winning facilities, more than 100,000 additional lives and billions of dollars in inpatient costs could be saved. 
Public Health England, in partnership with the University of Oxford, recently conducted a head-to-head evaluation of four commercial immunoassay tests available in the UK and used for the detection of SARS-CoV-2 antibodies.Siemens Healthineers' laboratory-based total antibody test(1) distinguished itself as the only assay tested found to meet both the sensitivity and specificity requirements set out within the Target Product Profile (TPP) for immunoassays by the UK Medicines and Healthcare products Regulatory Agency (MHRA). 
Abbott (NYSE: ABT) announced that the U.S. Food and Drug Administration (FDA) has approved the company's next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The devices bring new benefits to patients with heart rhythm disorders, including a patient-preferred design without compromising battery longevity and MRI compatibility.